Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Summary

This study is being done to look at the combination of the drugs atezolizumab and bevacizumab as a maintenance treatment (treatment given after the main treatment to keep the cancer from coming back or worsening) following standard therapy in patients with high grade ovarian, fallopian tube, or primary peritoneal cancer with a mutation (change) in a gene called TP53. Genes are molecules in the body that are made up of deoxyribonucleic acid (DNA) and control how the body's cells behave.

Timeline

Start

2021-07-16

Primary completion

2023-02-22

Completion

2023-02-22

Outcome

Outcome not reported

Stopped (Enrollment): “19 patients screenfailed, stopping recruitment before first patient enrollment to analyze pilot results from screening samples.”

Drugs

Indications